Answers are grounded in this paper and cite their sources.
Oligometastatic disease represents a variant of metastatic colorectal cancer in which complete local treatment of all identified lesions is feasible. Its criteria do not coincide with those of technical resectability. Aim of the work – to evaluate the indications and limitations of surgical treatment of resectable colorectal cancer metastases, with a primary focus on hepatic and pulmonary involvement. Results from surgical case series, randomized trials, and clinical guidelines are compared. Hepatic resection enables long-term survival in selected patients; the choice of extent of surgery is determined by the feasibility of complete tumor removal and preservation of functioning parenchyma. The benefit of perioperative and adjuvant chemotherapy with respect to overall survival remains unproven for the entire population of patients with resectable metastases. For pulmonary surgery, the evidence base is predominantly observational; the PulMiCC trial found no significant survival advantage from resection. The ORCHESTRA trial demonstrated no improvement in overall survival with the addition of local cytoreduction to systemic therapy in multiorgan disease. The results of the COLLISION trial support discussion of thermal ablation as an alternative to resection for small hepatic metastases. The selection of local treatment modality and treatment sequencing requires assessment of disease extent, tumor biology, and operative risk within a specialized multidisciplinary tumor board.
No takes yet. Share an insight, caveat, or question.
Расулов et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: